MX2016002763A - Formas cristalinas de un derivado de pirrolidona util en el tratamiento de la enfermedad de alzheimer y preparacion de las mismas. - Google Patents

Formas cristalinas de un derivado de pirrolidona util en el tratamiento de la enfermedad de alzheimer y preparacion de las mismas.

Info

Publication number
MX2016002763A
MX2016002763A MX2016002763A MX2016002763A MX2016002763A MX 2016002763 A MX2016002763 A MX 2016002763A MX 2016002763 A MX2016002763 A MX 2016002763A MX 2016002763 A MX2016002763 A MX 2016002763A MX 2016002763 A MX2016002763 A MX 2016002763A
Authority
MX
Mexico
Prior art keywords
alzheimer
disease
preparation
treatment
crystalline forms
Prior art date
Application number
MX2016002763A
Other languages
English (en)
Other versions
MX361764B (es
Inventor
Urs Schwitter
Michelangelo Scalone
Stefan Hildbrand
Olaf Grassmann
Ulrich Zutter
Roland Meier
Beat Wirz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016002763A publication Critical patent/MX2016002763A/es
Publication of MX361764B publication Critical patent/MX361764B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención proporciona procesos para fabricar la N-[(3S)-1-[4-[(3-fluorofenil)metoxi]fenil]-5-oxo-pirrolidin-3-il] acetamida cristalina. También se describen las formas polimórficas del compuesto así como los compuestos útiles como compuestos intermedios en los métodos de la invención.
MX2016002763A 2013-10-29 2014-10-27 Formas cristalinas de un derivado de pirrolidona util en el tratamiento de la enfermedad de alzheimer y preparacion de las mismas. MX361764B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13190612 2013-10-29
PCT/EP2014/072934 WO2015063001A1 (en) 2013-10-29 2014-10-27 Crystalline forms of a pyrrolidone derivative useful in the treatment of alzheimer's disease and preparation thereof

Publications (2)

Publication Number Publication Date
MX2016002763A true MX2016002763A (es) 2016-05-26
MX361764B MX361764B (es) 2018-12-17

Family

ID=49485638

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002763A MX361764B (es) 2013-10-29 2014-10-27 Formas cristalinas de un derivado de pirrolidona util en el tratamiento de la enfermedad de alzheimer y preparacion de las mismas.

Country Status (11)

Country Link
US (1) US9562009B2 (es)
EP (1) EP3063130A1 (es)
JP (1) JP2016535046A (es)
KR (1) KR20160067208A (es)
CN (1) CN105705487A (es)
BR (1) BR112016003288A8 (es)
CA (1) CA2920070A1 (es)
HK (1) HK1220203A1 (es)
MX (1) MX361764B (es)
RU (1) RU2016118748A (es)
WO (1) WO2015063001A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04342591A (ja) * 1990-07-10 1992-11-30 Nissan Chem Ind Ltd ピラノベンゾオキサジアゾール誘導体
PA8583001A1 (es) * 2002-09-20 2004-04-23 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b
US7148362B2 (en) * 2003-09-18 2006-12-12 Hoffmann-La Roche Inc. Process for the preparation of enantiopure pyrrolidin-2-one derivatives
ATE415388T1 (de) 2005-03-15 2008-12-15 Hoffmann La Roche Verfahren zur herstellung von enantiomerenreinen 4-pyrrolidinophenyl- benzyletherderivaten
US7501528B2 (en) * 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
CN103304438B (zh) * 2013-06-18 2015-12-02 山东大学 N-取代水杨酰胺类化合物、制备方法及应用

Also Published As

Publication number Publication date
BR112016003288A8 (pt) 2020-02-04
WO2015063001A1 (en) 2015-05-07
EP3063130A1 (en) 2016-09-07
CA2920070A1 (en) 2015-05-07
JP2016535046A (ja) 2016-11-10
MX361764B (es) 2018-12-17
US9562009B2 (en) 2017-02-07
KR20160067208A (ko) 2016-06-13
CN105705487A (zh) 2016-06-22
US20160237032A1 (en) 2016-08-18
RU2016118748A (ru) 2017-12-05
HK1220203A1 (zh) 2017-04-28
RU2016118748A3 (es) 2018-06-06

Similar Documents

Publication Publication Date Title
TN2015000429A1 (en) 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders
MX2020001602A (es) Inhibidor del antigeno-1 asociado a la funcion del linfocito (lfa-1) y polimorfo del mismo.
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
IN2014KN00948A (es)
EA201891642A1 (ru) Кристаллические формы ингибитора mdm2
UA108087C2 (uk) Тверді форми n-(4-(7-азабіцикло[2.2.1]гептан-7-іл)-2-(трифторметил)феніл)-4-оксо-5-(трифторметил)-1,4-дигідрохінолін-3-карбоксаміду
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
EA201171211A1 (ru) Производные оксадиазола
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
EA201391026A1 (ru) Кристаллическое производное оксазина и его применение в качестве ингибитора bace
PH12017500089A1 (en) Aldosterone synthase inhibitors
IN2013DN02555A (es)
EA201590074A1 (ru) Производное бензодиоксола, способ его получения и его применение
EA201170736A1 (ru) Синтез и новые солевые формы (r)-3-((e)-2-(пирролидин-3-ил)винил)-5-(тетрагидропиран-4-илокси) пиридина
MX2016002763A (es) Formas cristalinas de un derivado de pirrolidona util en el tratamiento de la enfermedad de alzheimer y preparacion de las mismas.
EA201270786A1 (ru) α-КРИСТАЛЛИЧЕСКАЯ ФОРМА КАРБАБЕНЗПИРИДА
PH12014502780A1 (en) Azetidine and piperidine compounds useful as pde10 inhibitors
NZ724424A (en) Pyrimidine derivatives for the treatment of bacterial diseases
NZ727251A (en) Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer’s

Legal Events

Date Code Title Description
FG Grant or registration